Journal article
Preserving Enhancement in Freeze-Dried Contrast Agent ST68: Examination of Excipients
International journal of pharmaceutics, v 396(1), pp 30-38
30 Aug 2010
PMID: 20540998
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The perfluorcarbon (perfluorobutane) ultrasound contrast agent ST68, composed of sonicated mixtures of non-ionic surfactants, is stable in solution for only a few weeks at 4°C. Freeze-drying critically diminished ST68’s ability to reflect ultrasound (its echogenicity). A method of incorporating specific lyoprotectants before lyophilization was investigated. Reintroduction of perfluorobutane to the protected freeze-dried sample, followed by reconstituting with preserved echogenicity. Glucose, trehalose, sucrose, and mannitol were tested at 100 mM and
in vitro
echogenicity data was collected from samples with dose concentrations of 50 µl/l to 300 µl/l. Glucose was found to be the best lyoprotectant providing an average (n=3) maximum peak enhancement of 23.2 ± 1.2 dB
in vitro
, measured at 5 MHz, 684 kPa, and a pulse repetition frequency (PRF) of 100 Hz (p<0.05 over freeze-dried ST68 control) and 20.8 ± 0.8 dB
in vivo
in New Zealand white rabbits at 5 MHz and a PRF of 6.7 kHz. Pulse inversion harmonic US images of a rabbit kidney, pre- and post-contrast injection (0.1 ml/kg), showed excellent enhancement and clear vascular delineation, similar to that of the original agent. For the first time this contrast agent can be successfully freeze-dried yielding a longer self-life without the need for refrigeration.
Metrics
Details
- Title
- Preserving Enhancement in Freeze-Dried Contrast Agent ST68: Examination of Excipients
- Creators
- Carl Solis - School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia Pa. 19104Flemming Forsberg - Department of Radiology, Thomas Jefferson University, Philadelphia Pa. 19107Margaret A Wheatley - School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia Pa. 19104
- Publication Details
- International journal of pharmaceutics, v 396(1), pp 30-38
- Publisher
- Elsevier
- Grant note
- R01 HL052901 || HL / National Heart, Lung, and Blood Institute : NHLBI
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems
- Web of Science ID
- WOS:000280936000005
- Scopus ID
- 2-s2.0-77955056587
- Other Identifier
- 991014877798004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Pharmacology & Pharmacy